Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 43 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Mirvetuximab soravtansine for advanced, epithelial ovarian, fallopian tube, or primary peritoneal cancer with high folate receptor-alpha expression	Mirvetuximab soravtansine (IMGN853)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2023	View \| Download
Lurbinectedin for platinum resistant ovarian cancer	Lurbinectedin (PM01183; Zepzelca)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2017	View \| Download
LN-145 for recurrent, metastatic or persistent cervical carcinoma	LN-145	Cervical cancer	Female Reproductive Cancer	2020	View \| Download
Lenvatinib in combination with Pembrolizumab for advanced or recurrent endometrial cancer - First Line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Endometrial cancer	Female Reproductive Cancer	2021	View \| Download
Lenvatinib in combination with pembrolizumab for advanced endometrial cancer – second line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Endometrial cancer	Female Reproductive Cancer	2020	View \| Download
Durvalumab with carboplatin and paclitaxel with or without olaparib for newly diagnosed advanced or reccurent endometrial cancer	Carboplatin (Paraplatin) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Paclitaxel (Taxol; paclitaxel albumin)	Endometrial cancer	Female Reproductive Cancer	2023	View \| Download
Durvalumab with bevacizumab and chemotherapy for treating advanced ovarian cancers	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Ovarian cancer	Female Reproductive Cancer	2023	View \| Download
Durvalumab add-on therapy for previously untreated locally advanced cervical cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Cervical cancer	Female Reproductive Cancer	2022	View \| Download
Dostarlimab with paclitaxel and carboplatin for recurrent or primary advanced endometrial cancer	Carboplatin (Paraplatin) , Dostarlimab (TSR-042; Jemperli) , Paclitaxel (Taxol; paclitaxel albumin)	Endometrial cancer	Female Reproductive Cancer	2023	View \| Download
Dostarlimab with chemotherapy and niraparib for treating advanced epithelial ovarian cancers – first line	Chemotherapy , Dostarlimab (TSR-042; Jemperli) , Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate)	Epithelial ovarian cancers	Female Reproductive Cancer	2023	View \| Download